Stephen K. VanDenEeden
Kaiser Permanente
10 Papers
11 Citations
Stephen K. VanDenEeden is an academic researcher from Kaiser Permanente. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 6 publications.
Chat about Author
Papers
Association of Testosterone Replacement With Cardiovascular Outcomes Among Men With Androgen Deficiency.
T. Craig Cheetham,Jaejin An,Steven J. Jacobsen,Fang Niu,Stephen Sidney,Charles P. Quesenberry,Stephen K. VanDenEeden +6 more
TL;DR: Among men with androgen deficiency, dispensed testosterone prescriptions were associated with a lower risk of cardiovascular outcomes over a median follow-up of 3.4 years, compared with 3.7 years in the never-TRT group.
163
Men Who Seek Infertility Care May Not Represent the General U.S. Population: Data From the National Survey of Family Growth
James M. Hotaling,Michael Davenport,Michael L. Eisenberg,Stephen K. VanDenEeden,Thomas J. Walsh +4 more
TL;DR: Marital status and education level were strongly associated with infertility care seeking, and men seeking infertility care in the United States tend to be married, older, and more educated than those not seeking care.
37
Development of an algorithm to identify metastatic prostate cancer in electronic medical records using natural language processing.
Lauren P. Wallner,Julia R. DiBello,Bonnie H. Li,Chengyi Zheng,Wei Yu,Sheila Weinmann,Kathryn Richert-Boe,Debra P. Ritzwoller,Stephen K. VanDenEeden,Steven J. Jacobsen +9 more
TL;DR: The results suggest that NLP can be used to identify men with metastatic prostate cancer in the EMR more accurately than diagnosis codes alone, and facilitates quality of care research in this setting to ensure the delivery of appropriate and high-quality care.
5
Testosterone Replacement Therapy and Cardiovascular Risk-A Closer Look to Additional Parameters.
TL;DR: The T-Trials population was not large enough nor the duration of observation long enough to provide definitive information about the risks of testosterone treatment in symptomatic older men with low testosterone, so a larger, longer, placebo-controlled trial is needed to determine the risks.
3
Valvular heart disease in patients exposed to pergolide: insights from the clinical presentation.
Ashok Krishnaswami,Kathleen B. Albers,Robin D. Fross,James J. Jang,Sarah Berkheimer,Valerie C. Kwai Ben,Stephen K. VanDenEeden +6 more
TL;DR: The aim of this study was to determine whether the presence of symptoms would aid in the detection of valvular heart disease (VHD) in those exposed to pergolide.
2